[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vasopressor-adverse-reaction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vasopressor-adverse-reaction":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100548590","registry-of-patients-in-shock-treated-with-vasopressin-100548590",false,"NCT06422975","Registry of Patients in Shock Treated With Vasopressin","Prospective Multicentre Observational Study of Patients Treated With Vasopressin in Critical Care Units","Inclusion Criteria:\n\n* Any patient over 18 years of age who is in shock and requires the administration of vasoconstrictors, to whom vasopressin is administered in the operating theatre and\u002For critical care unit, according to best clinical practice.\n\nExclusion Criteria:\n\n* Non-consent by patient\u002Flegal representatives","ALL","18 Years",{"count":19,"type":20},500,"ESTIMATED","90 Days","OBSERVATIONAL","Arginine-vasopressin (AVP) is a non-catecholaminergic hormone produced in the hypothalamus and released into the circulation via the neurohypophysis. It has different actions depending on the receptors through which it acts: V1 (vasoconstriction, platelet aggregation, efferent arteriole constriction of the renal glomerulus, glycogenolysis); V2 (water reabsorption, release of von Willebrand factor and factor VIII); V3 (increased cortisol and insulin).\n\nSeptic shock is the most common cause of vasoplegic shock and its management includes control of the focus, early antibiotic therapy, volume resuscitation, vasopressor therapy, support of various organ dysfunctions, as well as monitoring and follow-up.\n\nThe Surviving Sepsis Campaign (a global initiative to improve sepsis management) recommends noradrenaline as the first line of vasopressor therapy and early addition of AVP as a second line rather than further up-titration of noradrenaline when signs of hypoperfusion persist, through its action primarily on V1.\n\nThe rationale for its use in septic shock would be:\n\n* endogenous vasopressin deficiency present in septic shock;\n* as a catecholamine-sparing strategy, reducing the side effects of catecholamines;\n* its potential nephroprotective effect;\n* its use should be early.\n\nThe uncertainties surrounding the use of AVP in septic shock and other types of shock are many, hence the need for this registry.",[25,26,27,28],"Vasopressin Causing Adverse Effects in Therapeutic Use","Shock","Vasopressor Adverse Reaction","Vasopressin Deficiency",[30,26],"Vasopressin","RECRUITING","2024-07-11",{"date":34,"type":35},"2024-07-15","ACTUAL",{"date":37,"type":35},"2024-07-09",{"date":39,"type":20},"2026-06",{"name":41,"class":42},"Hospital Universitario 12 de Octubre","OTHER",24]